Effects of Lewis Y antigen on the gene expression of multiple drug resistance-associated proteins in human ovarian cancer RMG-I-H cells

Abstract

The effects of Lewis Y antigen on the gene expression of multiple drug resistance-associated proteins in human ovarian cancer RMG-I-H cells were unclear by now. In this study, we detected the gene expression of multiple drug resistance-associated proteins (MRP) in RMG-I-H cells and RMG-I-H cells treated with anti-Lewis Y monoclonal antibody to investigate the association between Lewis Y antigen and the gene expression of drug resistance-associated proteins. Compared with RMG-I cells, the expression of MRP1, MRP2, protein kinase C-alpha (PKC-alpha), and topoisomerase I (Topo I) mRNAs in RMG-I-H cells were significantly upregulated, while the MDR-1 mRNA was downregulated. Immunochemistry analyses indicated that the in vitro and in vivo expression levels of MDR-1 protein (P-gp) in RMG-I-H cells were significantly higher than those in RMG-I cells. After RMG-I-H cells were treated with anti-Lewis Y monoclonal antibody, the expression levels of MDR-1, MRP1, MRP2, PKC-alpha, and Topo I mRNAs gradually decreased with the prolongation of treatment duration. In contrast, no obvious changes were noted in the expression levels of these mRNAs in the non-treatment group. At 6 h after treatment, the relative levels of MDR-1, MRP1, MRP2, PKC-alpha, and Topo I mRNAs in the antibody treatment group were significantly lower than those in the non-treatment group. In conclusion, Lewis Y antigen is closely associated with regulating the gene expression of multiple drug resistance-associated proteins.

Lewis (y) Antigen Overexpression Increases the Expression of MMP-2 and MMP-9 and Invasion of Human Ovarian Cancer Cells

“…RMG-1-hFUT cell line, highly expressing Lewis (y) antigen, was established by transfecting the pcDNA3.1 (-)-HFUT-H expression vector (containing a1,2-FUT gene) into RMG-1 cells as previously described [16,17]. Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS, Hyclone, Logan, UT, USA) at 37 °C in a humidified 5% CO 2 atmosphere.…”

Relevant Role of Di-Fucosylated Ley Antigen in the Outcome of Locally Advanced Cervical Squamous Cell Carcinoma Patients Treated with Cisplatin Regimen

“…CD44 and increased levels of LeY antigen are associated with increased CD44-mediated epithelial ovarian cancer cells adhesion and migration as well as increased resistance to carboplatin and paclitaxel [8,24]. In our squamous cervical cancer study, we could not confirm this result.…”

“…

Research Article Open AccessRecently, Gao et al found that the di-fucosylated Lewis Y (LeY) antigen is part of the composition of CD44 and their increased expression is correlated with enhanced CD44-mediated cell adhesion and migration [8]. Also, increased expression of LeY antigen and CD44 were associated with elevated resistance to chemotherapeutic drugs such as platinum agents, taxanes, 5-fluorouracil, doxorubicin and mitomycin [9][10][11][12].

Although the effects of alternative splicing and post-translational glycosylation of CD44 on its interaction with HA have been studied in several tumor types, few data has described the effect of these alterations in LACSCC.

…”

Chemoresistance Is Associated with MUC1 and Lewis y Antigen Expression in Ovarian Epithelial Cancers

“…The expression of MUC1 positively correlates with the Lewis y antigen ( r s = 0.26, p < 0.05). We have previously shown that the Lewis y antigen is associated with multi-drug resistance in ovarian cancer [27]. Although no statistically significant difference in mortality was found between patients that differ in MUC1 and Lewis y antigen expression, this needs to be clarified with a longer follow-up.…”